Neonatal Lung Diseases
Neonatal Lung Diseases - Related Videos
11:26
Real-time X-ray Imaging of Lung Fluid Volumes in Neonatal Mouse Lung
0 Views •
Cited by 1 •
2016
We present a protocol to assess the rate of alveolar fluid clearance or pulmonary edema in neonatal mouse lung using X-ray imaging technology.
08:58
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
0 Views •
2025
This protocol describes the development of a neonatal piglet model of acute lung injury that models early pathogenic events occurring in the preterm lung, including sub-adequate surfactant quantity, hyperoxia, high-pressure ventilation, and inflammation, to facilitate understanding of molecular triggers of bronchopulmonary dysplasia and enhance therapeutic translation.
06:15
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
0 Views •
Cited by 152 •
2019
Lung ultrasound is a noninvasive and valuable tool for bedside evaluation of neonatal lung diseases. However, a relative lack of reference standards, protocols and guidelines may limit its application. Here, we aim to develop a standardized neonatal lung ultrasound diagnostic protocol to be used in clinical decision-making.
04:21
A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
0 Views •
Cited by 2 •
2021
This technique of instilling drugs directly into the trachea of neonatal rodents is important in studying the impact of locally administered drugs or biologicals on neonatal lung diseases. Additionally, this method can also be used for inducing lung injury in animal models.
06:14
Isolation of Alveolar Type II Epithelial Cells from Neonatal, Juvenile, and Adult Murine Lungs Adaptable to Infectious Experimental Settings
0 Views •
2025
This protocol presents a flow cytometry-based method to isolate viable alveolar type II epithelial cells (AECII) from neonatal, juvenile, or adult murine lungs (infected or non-infected). This approach enables downstream molecular and/or functional studies of AECII to identify their roles during lung inflammation and infection.
FAQs
Insufficient surfactant reduces alveolar stability, making the air spaces less able to remain open during breathing. This decreases the effective area available for gas exchange and can impair oxygen delivery. Recognizing this mechanism helps clinicians consider surfactant replacement as part of management when the newborn’s respiratory problem reflects inadequate surfactant function.
After birth, the lungs must shift from a fluid-filled fetal state to functioning air spaces that support independent respiration. When fetal lung fluid remains, this transition is disrupted, limiting efficient gas exchange. The resulting breathing difficulty illustrates why neonatal assessment must consider both developmental transition and possible injury or disease.
Infection and inflammation can injure developing lung tissue, while disrupted development may interfere with the normal formation or function of respiratory structures. These processes can compound problems caused by immature lungs, worsening gas exchange and oxygen delivery. Identifying the underlying contributor is therefore important because management may also require infection control or broader respiratory support.
Clinicians combine respiratory assessment with imaging and blood-gas measurements to characterize the newborn’s condition. Respiratory findings indicate the immediate functional problem, imaging can provide information about lung involvement, and blood gases help evaluate gas exchange. Together, these sources support identification of the underlying problem rather than relying on a single observation.
Evaluation begins with assessment of breathing and is supplemented by imaging and blood-gas measurements. This combination helps determine how severely gas exchange is affected and supports investigation of possible causes, such as insufficient surfactant, retained fetal lung fluid, infection, inflammation, or disrupted development. The findings guide decisions about respiratory support and other treatment.
Treatment is selected according to the respiratory problem identified during evaluation. Oxygen therapy can address impaired oxygen delivery, while respiratory support assists breathing when the newborn cannot maintain adequate function independently. Surfactant replacement may be considered when insufficient surfactant contributes to reduced alveolar stability. Infection control is added when infection or inflammation is part of the clinical concern.
Early diagnosis allows clinicians to identify the underlying respiratory problem and begin appropriate support before impaired gas exchange leads to additional complications. This is especially relevant because neonatal lung disease can affect long-term lung development. Current research therefore focuses on improving early recognition and reducing complications that may persist beyond the immediate newborn period.